Artivion (AORT) Investor presentation summary

Strategic focus and market position

• Specializes in aortic disease with a comprehensive portfolio, generating $444M revenue and $90M EBITDA in FY25.

• Holds leading positions in preservation services, mechanical heart valves, stent grafts, and surgical sealants, with high barriers to entry and limited competition.

• Global sales force of ~200 direct employees and a scalable infrastructure support expansion.

• Category-defining products and expanding market leadership in aortic interventions.

Product innovation and clinical outcomes

• On-X mechanical heart valve shows 87% reduction in major bleeding and is the only valve indicated for low INR (1.5–2.0), with 21% YoY growth in FY25.

• New clinical data supports significant mortality benefit and durability for mechanical valves in younger patients.

• AMDS hybrid prosthesis and NEXUS stent grafts demonstrate improved patient outcomes and high survival rates in pivotal trials.

• Ross procedure with decellularized homografts shows excellent long-term survival, comparable to the general population.

Financial performance and growth drivers

• Sustained double-digit revenue growth and EBITDA growth at twice the rate of revenue, driven by high-margin products and global expansion.

• FY26 revenue guidance of $480M–$496M (7–11% growth) and adjusted EBITDA guidance of $92M–$99M (26% growth).

• Gross margin expansion and operating leverage from product mix, sales force, and G&A infrastructure.

• Consistent investment in R&D (~7–8% of sales) supports a robust pipeline and future market opportunities.